Accueil / Communiqués / Oragenics, Inc. Receives Further Validation for Lantibiotic Compound OG716

Oragenics, Inc. Receives Further Validation for Lantibiotic Compound OG716

Monday, January 28th 2019 at 1:37pm UTC

TAMPA, Fla.–(BUSINESS WIRE)– Oragenics, Inc. (NYSE American: OGEN), a leader in the development of
new antibiotics against infectious diseases and effective treatments for
oral mucositis (“OM”), today announces the publication of a preclinical
study using the lead compound from its lantibiotics program, OG716, in
the peer reviewed journal, Antimicrobial Agents and Chemotherapy.

The preclinical study demonstrated that following oral administration of
the maximum feasible dose of OG716 in hamster models, there were no
observable toxicities nor observable side effects, nor was there any
effect on intestinal motility. Treatment of animals infected with C.
difficile
resulted in a dose-dependant survival, and no recurrence
at the upper dose tested. Further, researchers observed that the
compound remained constrained only in the gastrointestinal tract.
Lantibiotics, including OG716, are a novel class of peptide
antibacterial compounds naturally produced by a variety of Gram-positive
bacteria. Oragenics’ lantibiotic library offers a large pipeline for the
development of novel antibiotics in several indications.

“The publication of this study offers additional validation for the
safety and tolerability of our lantibiotic program, while simultaneously
confirming the potential for our lead candidate for the treatment of
CDAD,” stated Alan Joslyn, Ph.D., President and CEO of Oragenics, Inc.
“There exists a dire need for new approaches to fighting
antibiotic-resistant infections, and we believe the continued
development of our lantibiotic program is one of those potential
solutions. We look forward to providing continued updates on the
development of OG716 as they become available.”

The manuscript is available on-line at https://aac.asm.org/content/early/2019/01/17/AAC.01904-18.

About Lantibiotics and OG716

OG716 is a molecule derived from Oragenics’ lantibiotic discovery and
characterization platform that has shown positive results in nonclinical
testing including efficacy in an animal model for Clostridium
difficile
infection in enteritis. Lantibiotics are a class of
antibiotic compounds with novel mechanism of action, prized for their
ability to overcome antibiotic-resistant infections. With resistant
strains on the rise, particularly healthcare-acquired infections (HAI),
the need for these potent lantibiotic agents is critical. Oragenics is
pursuing the commercial-scale production of a lantibiotic for use as an
antimicrobial.

About Oragenics, Inc.

We are focused on becoming a leader in novel antibiotics against
infectious disease and on developing effective treatments for oral
mucositis. Oragenics, Inc. has established two exclusive worldwide
channel collaborations with Intrexon Corporation and its subsidiaries.
The collaborations allow Oragenics to accelerate the development of much
needed new antibiotics that can work against resistant strains of
bacteria and the development of biotherapeutics for oral mucositis and
other diseases and conditions of the oral cavity, throat, and esophagus.

For more information about Oragenics, please visit www.oragenics.com.

Safe Harbor Statement: Under the Private Securities Litigation
Reform Act of 1995: This release includes forward-looking statements
that reflect management’s current views with respect to future events
and performance. These forward-looking statements are based on
management’s beliefs and assumptions and information currently
available. The words “believe,” “ expect,” “ anticipate,” “ intend,” “
estimate,” “ project” and similar expressions that do not relate solely
to historical matters identify forward-looking statements. Investors
should be cautious in relying on forward-looking statements because they
are subject to a variety of risks, uncertainties, and other factors that
could cause actual results to differ materially from those expressed in
any such forward-looking statements. These factors include, but are not
limited to, risks and uncertainties described in our filings with the
U.S. Securities and Exchange Commission. Oragenics assumes no
responsibility to update any forward-looking statements contained in
this press release or with respect to the matters described herein.

Contacts

Oragenics, Inc.
Corporate:
Michael Sullivan,
813-286-7900
Chief Financial Officer
msullivan@oragenics.com
or
Investors:
John
Marco
Managing Director
CORE IR
310-819-2948
johnm@coreir.com

Media:
Jules Abraham
CORE
IR
917-885-7378
julesa@coreir.com

Source: Oragenics, Inc.


Voir aussi

Maverick Therapeutics to Unveil Pre-Clinical Data on Novel COBRATM Platform at American Association for Cancer Research 2019 Annual Meeting

Saturday, March 30th 2019 at 12:00pm UTC – Pre-clinical Data Characterize the Conditional and Potent …